|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Attendance and compliance with an exercise program during localized breast cancer treatment in a randomized controlled trial: The PACT study.
|
31067223 |
2019 |
|
Movement Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
A truncated PACT protein resulting from a frameshift mutation reported in movement disorder DYT16 triggers caspase activation and apoptosis.
|
31246344 |
2019 |
|
Condyloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO<sub>2</sub> ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial.
|
30236042 |
2019 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Attendance and compliance with an exercise program during localized breast cancer treatment in a randomized controlled trial: The PACT study.
|
31067223 |
2019 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>PRKRA</i>/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.
|
30305341 |
2019 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>PRKRA</i>/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.
|
30305341 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>PRKRA</i>/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.
|
30305341 |
2019 |
|
Mental disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Patients are recruited to receive primary care through SMI PACT based on having a serious mental illness that is manageable with treatment, and elevated risk for hospitalization or death.
|
29880047 |
2018 |
|
Infections, Arenavirus
|
0.010 |
Biomarker
|
group |
BEFREE |
To understand the biological roles of PACT and RIG-I in authentic arenavirus infection, we analyze growth kinetics of recombinant Pichinde virus (PICV), a prototypical arenavirus, in RIG-I knockout (KO) and PACT KO mouse embryonic fibroblast (MEF) cells.
|
29669840 |
2018 |
|
Rest pain
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study.
|
29798770 |
2018 |
|
Congenital Abnormality
|
0.010 |
Biomarker
|
group |
BEFREE |
We therefore report a mutational analysis of GSC, HOXA2 and PRKRA in 106 congenital microtia patients without any combined malformation to explore the relationship between GSC, HOXA2, PRKRA and nonsyndromic microtia.
|
28109504 |
2017 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Together, our findings indicate a possible role of PACT in regulating the Cardiovirus-triggered immune responses mediated by MDA5 and LGP2, which opens the door to novel therapeutic strategies in interferon-related autoimmune diseases and cancer.
|
29032202 |
2017 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Together, our findings indicate a possible role of PACT in regulating the Cardiovirus-triggered immune responses mediated by MDA5 and LGP2, which opens the door to novel therapeutic strategies in interferon-related autoimmune diseases and cancer.
|
29032202 |
2017 |
|
Encephalitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In vitro interaction analyses using purified recombinant proteins confirmed that the single-stranded Theiler's murine encephalitis virus genome enhanced the interaction between LGP2 and PACT.
|
29032202 |
2017 |
|
Congenital small ears
|
0.010 |
Biomarker
|
disease |
BEFREE |
We therefore report a mutational analysis of GSC, HOXA2 and PRKRA in 106 congenital microtia patients without any combined malformation to explore the relationship between GSC, HOXA2, PRKRA and nonsyndromic microtia.
|
28109504 |
2017 |
|
Cardiovirus Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
PACT is required for MDA5-mediated immunoresponses triggered by Cardiovirus infection via interaction with LGP2.
|
29032202 |
2017 |
|
Deformity
|
0.010 |
Biomarker
|
group |
BEFREE |
We therefore report a mutational analysis of GSC, HOXA2 and PRKRA in 106 congenital microtia patients without any combined malformation to explore the relationship between GSC, HOXA2, PRKRA and nonsyndromic microtia.
|
28109504 |
2017 |
|
Neurodegenerative Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
A role for PKR and PACT in inflammatory processes linked to neurodegenerative diseases has been proposed and raised interest for pharmacological PKR inhibitors.
|
29170442 |
2017 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Together, our findings indicate a possible role of PACT in regulating the Cardiovirus-triggered immune responses mediated by MDA5 and LGP2, which opens the door to novel therapeutic strategies in interferon-related autoimmune diseases and cancer.
|
29032202 |
2017 |
|
Peripheral Arterial Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
IN.PACT™ Admiral™ drug-coated balloon: Durable, consistent and safe treatment for femoropopliteal peripheral artery disease.
|
27771367 |
2017 |
|
Limb ischemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Analysis of IN.PACT DEEP trial on the association between changes in perfusion from pre- to postrevascularization and clinical outcomes in critical limb ischemia.
|
28862375 |
2017 |
|
Peripheral arterial stenosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
IN.PACT™ Admiral™ drug-coated balloon: Durable, consistent and safe treatment for femoropopliteal peripheral artery disease.
|
27771367 |
2017 |
|
Advanced lung cancer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The aim of the PACT study is to identify the information and decision support needs of patients, leading to the development of an intervention to support patients with advanced lung cancer when considering treatment options.
|
28706092 |
2017 |
|
Eczema
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We further identified previously unreported pleiotropic alleles with opposing effects on atopic dermatitis and psoriasis risk in PRKRA and ANXA6/TNIP1.
|
25574825 |
2015 |
|
Parkinsonism-Dystonia, Infantile
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Other entities entailing dystonia-parkinsonism include dopamine transporter deficiency syndrome (SLC63 mutations); dopa-responsive dystonias; young-onset parkinsonism (PARKIN, PINK1 and DJ-1 mutations); PRKRA mutations; and X-linked TAF1 mutations, which rarely can also manifest in women.
|
25643588 |
2015 |